Trial Profile
PERSIST: PROSPECTIVE OBSERVATIONAL COHORT STUDY TO ASSESS PERSISTENCE OF CT-P13 (INFLIXIMAB) IN PATIENTS WITH RHEUMATOID DISEASES WHO ARE EITHER NAIVE TO BIOLOGICS OR SWITCHED FROM STABLE REMICADE(R) (INFLIXIMAB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PERSIST
- Sponsors Pfizer
- 30 Apr 2020 Results of post marketing pooled analysis of six observational studies published in the BioDrugs
- 15 Jun 2019 Interim results (n=329) presented at the 20th Annual Congress of the European League Against Rheumatism
- 15 Jun 2019 Results assessing pooled analysis of this and other three global post-marketing studies (KOREA PMS, CT-P13 4.4, and CT-P13 4.2) presented at the 20th Annual Congress of the European League Against Rheumatism